BACKGROUND The development of selective atrial antiarrhythmic agents is a current strategy for suppression of atrial fibrillation (AF). METHODS AND RESULTS Whole-cell patch clamp techniques were used to evaluate inactivation of peak sodium channel current (I(Na)) in myocytes isolated from canine atria and ventricles. The electrophysiological effects of therapeutic concentrations of ranolazine...

BACKGROUND Treatments for patients with myocardial ischemia in the absence of angiographic obstructive coronary artery disease are limited. In these patients, particularly those with diabetes mellitus, diffuse coronary atherosclerosis and microvascular dysfunction is a common phenotype and may be accompanied by diastolic dysfunction. Our primary aim was to determine whether ranolazine would qua...

BACKGROUND Amiodarone and ranolazine have been characterized as inactivated- and activated-state blockers of cardiac sodium channel current (I(Na)), respectively, and shown to cause atrial-selective depression of I(Na)-related parameters. This study tests the hypothesis that their combined actions synergistically depress I(Na)-dependent parameters in atria but not ventricles. METHODS AND RESU...

OBJECTIVES The purpose of this study was to determine if ranolazine improves angina in stable coronary patients with persisting symptoms despite maximum recommended dose of amlodipine. BACKGROUND Ranolazine is a unique antianginal agent that has been effective in stable angina, but it has not been studied in the setting of maximum recommended doses of conventional antianginal agents. METHOD...

p T n this issue of the Journal, Sossalla et al. (1) present an nteresting article on alterations of the Na current (INa) in trial myocytes of patients with persistent atrial fibrillation AF) and the effects of ranolazine, an orally active piperaine derivative, on these currents. Although peak INa was lightly lower in AF patients compared with patients in inus rhythm (SR), the late and sustaine...

The present study assesses whether ranolazine increases left ventricular (LV) function without an increase in myocardial oxygen consumption (MVO2) and thus improves LV mechanical efficiency in dogs with heart failure (HF). Ranolazine did not change MVO2 and LV mechanical efficiency increased (22.4+/-2.8% to 30.9+/-3.4% (P<0.05). In contrast, dobutamine significantly increased MVO2 and did not i...

SoC and SoC alone gained 0.3155 QALYs and 0.2752 QALYs, respectively. Hence, ranolazine plus SoC resulted in an ICER of € 4,620 per QALY gained, well below the threshold of € 34,000 per QALY gained, that is twice the annual per capita income. The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at the threshold of € 34,000 per QALY gained was 100%. ConClusions: The res...

Ranolazine, an anti-anginal drug, is a late Na(+) channel current blocker that is also believed to attenuate fatty acid oxidation and mitochondrial respiratory complex I activity, especially during ischemia. In this study, we investigated if ranolazine's protective effect against cardiac ischemia/reperfusion (IR) injury is mediated at the mitochondrial level and specifically if respiratory comp...

BACKGROUND After defibrillation of initial ventricular fibrillation (VF), it is crucial to prevent refibrillation to ensure successful resuscitation outcomes. Inability of the late Na+ current to inactivate leads to intracellular Ca2+ dysregulation and arrhythmias. Our aim was to determine the effects of ranolazine and GS-967, inhibitors of the late Na+ current, on ventricular refibrillation. ...

. Morrow DA, Scirica BM, Sabatine MS, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non–ST-segment elevation acute coronary syndromes: observations from the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-STElevation Acute Coronary–Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2010;55:1189–96. . Scirica BM, Mor...